Full-Time
Software Engineer-Language Services
Icon
10,001+ employees
Consulting and development services for pharmaceuticals
No salary listed
Mid
Madrid, Spain + 1 more
More locations: Sant Cugat del Vallès, Barcelona, Spain
Remote
- A Bachelor’s degree in Computer Science, Software Engineering, or a related field
- 3+ years of experience as a Software Engineer in a collaborative development environment
- Strong knowledge of PHP and experience writing clean, maintainable code
- Proficiency with TypeScript and/or JavaScript
- Hands-on experience with a data-driven UI framework, such as VueJS, React, or similar
- Solid understanding of Object-Oriented (OO) design principles, and confidence in designing systems and features
- Comfort working with SQL and an understanding of database design best practices
- Some experience with automated testing to ensure software quality and reliability
- Design, develop, and maintain software solutions under the direction of a Team Lead or designee, ensuring your work aligns with project goals and timelines
- Deliver high-quality results within agreed timeframes, consistently meeting expectations for performance and reliability
- Solve technical problems in your area of responsibility, using your knowledge and creativity to address issues—escalating when necessary
- Follow defined processes and procedures, proactively highlighting any gaps, inefficiencies, or risks that may impact delivery or quality
- Execute assigned objectives efficiently and effectively, with guidance from senior team members as needed
- Continuously build your technical skills, gaining experience with relevant technologies and best practices
- Provide regular status updates to your manager or lead, flagging any obstacles or blockers early
- Collaborate and contribute to the team, offering assistance and knowledge-sharing to support shared development goals
- Assist with project planning, working with project managers or scrum masters to help ensure timelines stay on track
Icon provides consulting, development, and commercialization services to help clients in the pharmaceutical and medical device industries accelerate the creation of products that enhance health and well-being. Their services are designed to streamline the process of bringing drugs and devices to market by focusing on reducing time and costs while improving quality. With a presence in 53 countries, Icon leverages a global network of experts who have experience across various therapeutic areas. This extensive expertise allows them to tailor their solutions to meet the specific needs of their clients, setting them apart from competitors who may not offer the same level of specialized support. Icon's goal is to ensure that life-saving and life-enhancing products reach the market efficiently and effectively.
Company Size
10,001+
Company Stage
IPO
Headquarters
Ireland
Founded
1990
Simplify's Take
What believers are saying
- Increased use of AI accelerates clinical trial participant identification.
- Partnership with Mural Health enhances trial participant and site experience.
- Centre for Obesity expedites obesity-related clinical trials.
What critics are saying
- Complexity of multi-indication trials may lead to inefficiencies.
- Securities fraud lawsuit could cause financial and reputational damage.
- Underutilization of biomarkers may hinder optimization of neurodegenerative trials.
What makes Icon unique
- ICON offers a global network of offices in 53 countries.
- The company focuses on reducing time to market, cost, and increasing quality.
- ICON has extensive experience in a broad range of therapeutic areas.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Health Insurance
Paid Vacation
401(k) Retirement Plan
Mental Health Support
Life Insurance
Flexible Work Hours
Company News
At Bio€quity Europe 2025, the premier investor conference for European biopharma, ICON was proud to contribute to the conversation shaping the future of early-stage innovation.
Alongside the whitepaper, ICON has launched their new Centre for Obesity that delivers expertise and market intelligence with a ready-to-deploy infrastructure of 100 sites and an in-development database of 10,000 pre-screened patients across the breadth of comorbidities related to obesity.
Dublin, Ireland – 7 May – ICON plc, (NASDAQ: ICLR) a world-leading clinical research organisation powered by healthcare intelligence, today released the findings of a survey of 155 biotech and pharma professionals from across the US and Europe focusing on multi-indication cardiometabolic RD for therapies targeting obesity and its comorbidities. Multi-indication studies are clinical trials that test how a treatment works for more than one condition or disease. As researchers uncover the potential of particular drug classes across interconnected diseases, the commercial opportunities have increased the appetite for additional research that targets multiple indications. The findings indicate that most sponsors (83% of respondents) are pursuing multi-indication approaches in their obesity-related research. However, the survey results also suggest that sponsors may underestimate the complexity of these strategies - particularly when selecting inclusion criteria and endpoints - which can lead to inefficiencies in the clinical development process
After Oxford Outcomes was acquired by ICON Plc. she honed her expertise in real world evidence (RWE), spending a lot of her time on multi-national projects including prospective studies, retrospective database and chart reviews, and eliciting patient, caregiver and provider perspectives.
ICON Public Limited Company (ICLR), a leading healthcare and pharmaceutical services provider, has been hit by a securities fraud class-action lawsuit.